Which has higher valuation & earnings, EXEL or NAMS?

Exelixis has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.78 $782.57M $3.18 17.01 NewAmsterdam Pharma $22.50M 148.07 -$203.82M -$2.16 N/A

Does the media favor EXEL or NAMS?

In the previous week, Exelixis had 12 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for Exelixis and 4 mentions for NewAmsterdam Pharma. Exelixis' average media sentiment score of 1.18 beat NewAmsterdam Pharma's score of 0.89 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or NAMS?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat NewAmsterdam Pharma's score of 0.89 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAMS or MDGL?

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat NewAmsterdam Pharma's score of 0.89 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or NAMS?

In the previous week, Halozyme Therapeutics had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 4 mentions for NewAmsterdam Pharma. Halozyme Therapeutics' average media sentiment score of 1.04 beat NewAmsterdam Pharma's score of 0.89 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NAMS or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.89 beat Summit Therapeutics' score of 0.37 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

NewAmsterdam Pharma (NAMS) Competitors

$27.87 +0.09 (+0.32%)

As of 08/21/2026 04:00 PM Eastern

Compare

NAMS vs. EXEL, ARWR, MDGL, HALO, and SMMT

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Exelixis?

Exelixis (NASDAQ:EXEL) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Exelixis had 12 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for Exelixis and 4 mentions for NewAmsterdam Pharma. Exelixis' average media sentiment score of 1.18 beat NewAmsterdam Pharma's score of 0.89 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Exelixis' return on equity of 42.17% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Exelixis presently has a consensus target price of $50.07, suggesting a potential downside of 7.42%. NewAmsterdam Pharma has a consensus target price of $49.33, suggesting a potential upside of 77.01%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Exelixis has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A

85.3% of Exelixis shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Exelixis beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 11.74%. NewAmsterdam Pharma has a consensus price target of $49.33, indicating a potential upside of 77.01%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat NewAmsterdam Pharma's score of 0.89 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Madrigal Pharmaceuticals?

NewAmsterdam Pharma (NASDAQ:NAMS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat NewAmsterdam Pharma's score of 0.89 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NewAmsterdam Pharma currently has a consensus target price of $49.33, suggesting a potential upside of 77.01%. Madrigal Pharmaceuticals has a consensus target price of $689.93, suggesting a potential upside of 33.52%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

NewAmsterdam Pharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market.

NewAmsterdam Pharma has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

NewAmsterdam Pharma beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Halozyme Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Halozyme Therapeutics' return on equity of 260.98% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Halozyme Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A

Halozyme Therapeutics currently has a consensus price target of $91.20, indicating a potential downside of 15.69%. NewAmsterdam Pharma has a consensus price target of $49.33, indicating a potential upside of 77.01%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, Halozyme Therapeutics had 11 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 4 mentions for NewAmsterdam Pharma. Halozyme Therapeutics' average media sentiment score of 1.04 beat NewAmsterdam Pharma's score of 0.89 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats NewAmsterdam Pharma on 11 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

NewAmsterdam Pharma currently has a consensus target price of $49.33, suggesting a potential upside of 77.01%. Summit Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 84.24%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Summit Therapeutics	N/A	-168.94%	-141.92%

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, Summit Therapeutics had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.89 beat Summit Therapeutics' score of 0.37 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.33B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-12.90	11.62	272.60	24.24
Price / Sales	148.07	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	5.28	16.80	13.05	6.20
Net Income	-$203.82M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.30%	3.29%	2.09%	0.08%
1 Month Performance	-8.77%	8.23%	6.64%	3.88%
1 Year Performance	11.48%	55.05%	25.02%	16.98%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	3.1074 of 5 stars	$27.87 +0.3%	$49.33 +77.0%	+11.5%	$3.33B	$22.50M	N/A	4
EXEL Exelixis	3.3853 of 5 stars	$51.33 -3.1%	$49.79 -3.0%	+40.0%	$12.90B	$2.32B	16.14	1,077	News Coverage Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2395 of 5 stars	$89.24 +1.0%	$97.33 +9.1%	+308.4%	$12.57B	$829.45M	N/A	400	News Coverage Insider Trade
MDGL Madrigal Pharmaceuticals	3.8051 of 5 stars	$535.27 +3.9%	$689.93 +28.9%	+24.6%	$12.37B	$1.28B	N/A	90	Positive News Insider Trade
HALO Halozyme Therapeutics	3.8909 of 5 stars	$102.62 flat	$91.20 -11.1%	+50.6%	$12.17B	$1.66B	30.63	390	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. EXEL, ARWR, MDGL, HALO, and SMMT

How does NewAmsterdam Pharma compare to Exelixis?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Summary

How does NewAmsterdam Pharma compare to Madrigal Pharmaceuticals?

Summary

How does NewAmsterdam Pharma compare to Halozyme Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. EXEL, ARWR, MDGL, HALO, and SMMT

How does NewAmsterdam Pharma compare to Exelixis?

Does the media favor EXEL or NAMS?

Which has more volatility & risk, EXEL or NAMS?

Is EXEL or NAMS more profitable?

Do analysts prefer EXEL or NAMS?

Which has higher valuation & earnings, EXEL or NAMS?

Do insiders & institutionals have more ownership in EXEL or NAMS?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Is ARWR or NAMS more profitable?

Do insiders & institutionals believe in ARWR or NAMS?

Do analysts rate ARWR or NAMS?

Which has more volatility & risk, ARWR or NAMS?

Which has better earnings and valuation, ARWR or NAMS?

Does the media refer more to ARWR or NAMS?

Summary

How does NewAmsterdam Pharma compare to Madrigal Pharmaceuticals?

Do insiders and institutionals have more ownership in NAMS or MDGL?

Does the media prefer NAMS or MDGL?

Do analysts prefer NAMS or MDGL?

Which has more risk & volatility, NAMS or MDGL?

Which has preferable valuation & earnings, NAMS or MDGL?

Is NAMS or MDGL more profitable?

Summary

How does NewAmsterdam Pharma compare to Halozyme Therapeutics?

Which has more risk and volatility, HALO or NAMS?

Do insiders & institutionals have more ownership in HALO or NAMS?

Is HALO or NAMS more profitable?

Which has higher valuation & earnings, HALO or NAMS?

Do analysts prefer HALO or NAMS?

Does the media favor HALO or NAMS?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Do analysts recommend NAMS or SMMT?

Which has more volatility & risk, NAMS or SMMT?

Is NAMS or SMMT more profitable?

Which has stronger valuation & earnings, NAMS or SMMT?

Does the media refer more to NAMS or SMMT?

Do insiders and institutionals have more ownership in NAMS or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools